X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1402) 1402
Publication (83) 83
Book Chapter (18) 18
Book Review (15) 15
Dissertation (5) 5
Government Document (3) 3
Conference Proceeding (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
myelosuppression (1182) 1182
humans (668) 668
index medicus (451) 451
male (431) 431
female (429) 429
chemotherapy (406) 406
oncology (355) 355
middle aged (303) 303
animals (302) 302
adult (276) 276
cancer (266) 266
pharmacology & pharmacy (266) 266
toxicity (243) 243
aged (242) 242
mice (207) 207
hematology (180) 180
neutropenia (175) 175
therapy (146) 146
bone marrow (145) 145
colony-stimulating factor (143) 143
azathioprine (124) 124
patients (124) 124
pharmacogenetics (124) 124
antineoplastic agents - adverse effects (115) 115
treatment outcome (115) 115
neutropenia - chemically induced (107) 107
care and treatment (105) 105
bone marrow - drug effects (103) 103
hematopoiesis (102) 102
analysis (98) 98
methyltransferases - genetics (95) 95
cyclophosphamide (93) 93
thrombocytopenia (92) 92
survival (91) 91
risk factors (90) 90
medicine & public health (89) 89
6-mercaptopurine (88) 88
antineoplastic combined chemotherapy protocols - therapeutic use (88) 88
dose-response relationship, drug (88) 88
drug therapy (86) 86
adolescent (85) 85
health aspects (85) 85
research (83) 83
tumors (80) 80
leukemia (79) 79
blood (78) 78
medicine, research & experimental (78) 78
drug administration schedule (76) 76
transplantation (76) 76
antineoplastic combined chemotherapy protocols - adverse effects (75) 75
pharmacokinetics (75) 75
clinical trials (73) 73
complications and side effects (73) 73
pharmacology/toxicology (72) 72
side effects (71) 71
aged, 80 and over (70) 70
induced myelosuppression (70) 70
neoplasms - drug therapy (70) 70
cancer therapies (68) 68
cisplatin (68) 68
stem cells (68) 68
cells (66) 66
thiopurine s-methyltransferase (66) 66
genotype (65) 65
retrospective studies (65) 65
apoptosis (64) 64
dosage and administration (64) 64
immunology (64) 64
acute lymphoblastic-leukemia (63) 63
trial (63) 63
inflammatory-bowel-disease (62) 62
azathioprine - adverse effects (61) 61
drugs (61) 61
hematopoiesis - drug effects (61) 61
pharmacology (61) 61
antineoplastic agents - therapeutic use (60) 60
hemopoiesis (59) 59
radiation (57) 57
hematopoietic stem cells - drug effects (56) 56
progenitor cells (56) 56
rats (56) 56
cell biology (55) 55
drug dosages (55) 55
time factors (55) 55
anemia (54) 54
antineoplastic agents (53) 53
breast cancer (53) 53
article (52) 52
azathioprine-induced myelosuppression (52) 52
medicine (52) 52
toxicology (52) 52
cytokines (51) 51
doxorubicin (51) 51
leukocyte count (51) 51
children (50) 50
hematopoietic stem cells (50) 50
young adult (50) 50
child (49) 49
immunosuppressive agents - adverse effects (49) 49
medicine, general & internal (49) 49
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1358) 1358
Chinese (17) 17
French (11) 11
German (11) 11
Japanese (11) 11
Spanish (10) 10
Russian (6) 6
Korean (3) 3
Polish (3) 3
Italian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancers, ISSN 2072-6694, 09/2019, Volume 11, Issue 9, p. 1294
The unsatisfactory real-world efficacy of the hypomethylating agent azacitidine in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)... 
myelosuppression | azacitidine | myelodysplastic syndromes
Journal Article
대한피부과학회지, ISSN 0494-4739, 2018, Volume 56, Issue 4, pp. 265 - 268
Azathioprine is an immunosuppressive drug that has been widely used in dermatology for the treatment of immunobullous diseases. Myelosuppression is the most... 
Azathioprine | Myelosuppression | Cytopenia | 피부과학
Journal Article
Korean Journal of Dermatology, ISSN 0494-4739, 05/2018, Volume 56, Issue 4, pp. 265 - 268
Journal Article
Journal Article
Journal of Obstetrics and Gynaecology Canada, ISSN 1701-2163, 05/2019, Volume 41, Issue 5, pp. 729 - 729
Journal Article
The Journal of Nuclear Medicine, ISSN 0161-5505, 05/2018, Volume 59, p. 121
Aim: $$_{41DEA31B-F33F-4691-8B9C-4F1EF9290325}$$ 5 010818hk draftv5 4FGLN word count 265 without title and authors 
Radioactive materials | Positron emission | Tomography | Myelosuppression | Medical disorders
Journal Article
Journal of Ginseng Research, ISSN 1226-8453, 10/2019, Volume 43, Issue 4, pp. 618 - 624
Ginsenoside Re (Re) is one of the major components of Meyer. Ginsenoside Rk (Rk ) is a secondary metabolite of Re. The aim of this study was to investigate and... 
Myelosuppression | Chemotherapy | Ginsenoside Rk3 | Ginsenoside Re | 기타의약학
Journal Article
Journal of Ultrasound in Medicine, ISSN 0278-4297, 10/2019, Volume 38, Issue 10, pp. 2721 - 2731
Objective This study aimed to investigate the effect of low‐intensity pulsed ultrasound (LIPUS) on cyclophosphamide (CTX)‐induced rabbit myelosuppression.... 
treatment | rabbit model | low‐intensity pulsed ultrasound | bone marrow hyperplasia | cyclophosphamide‐induced myelosuppression | ACOUSTICS | low-intensity pulsed ultrasound | COLONY-STIMULATING FACTOR | MECHANISMS | AGENTS | cyclophosphamide-induced myelosuppression | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CHEMOTHERAPY
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 3, pp. 213 - 223
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2017, Volume 377, Issue 26, pp. 2531 - 2544
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 02/2019, Volume 46, Issue 2, pp. e59 - e61
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1738 - 1748
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 18, pp. 1691 - 1703
In this report, the addition of nab-paclitaxel to standard gemcitabine increased the response rate, progression-free survival, and overall survival among... 
PHASE-III TRIAL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | PLACEBO | ONCOLOGY-GROUP | MONOTHERAPY